Division of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, 350 West Thomas Road, Phoenix, AZ 85013, USA.
J Neuroimmunol. 2011 Jun;235(1-2):9-17. doi: 10.1016/j.jneuroim.2011.01.009. Epub 2011 Mar 13.
Glatiramer acetate (GA, Copaxone®, co-polymer 1) is an immunomodulatory therapy approved in 1996 by the United States Food and Drug Administration for treatment of relapsing-remitting multiple sclerosis. GA has a good safety profile, moderate efficacy, and a unique mode of action. Recent evidence in an animal model of MS, experimental autoimmune encephalomyelitis (EAE), suggests that GA effects on NK cells and B cells may contribute to therapeutic efficacy. We review the mechanism of action of GA, with particular focus on recent data suggesting a role for regulatory B cells.
醋酸格拉替雷（GA，Copaxone®，共聚物 1）是一种免疫调节疗法，于 1996 年获得美国食品和药物管理局批准，用于治疗复发缓解型多发性硬化症。GA 具有良好的安全性、中等的疗效和独特的作用模式。最近在多发性硬化症的动物模型——实验性自身免疫性脑脊髓炎（EAE）中的证据表明，GA 对自然杀伤细胞和 B 细胞的作用可能有助于其治疗效果。我们综述了 GA 的作用机制，特别关注最近的数据表明调节性 B 细胞可能发挥作用。
